BRAINSTORM CELL THERAPEUTICS INC.

BCLI | OTC | CIK: 0001137883 | SIC: 2836 Biological Products, (No Diagnostic Substances) | active
United States (specific city not mentioned); R&D center in Petach Tikva, Israel
Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on developing autologous cellular therapies for neurodegenerative diseases including ALS, progressive multiple sclerosis, and Alzheimer's disease. Its proprietary NurOwn platform induces bone marrow-derived mesenchymal stem cells to secrete neurotrophic factors, modulate neuroinflammation, and promote neuronal survival. NurOwn has completed Phase 3 ALS and Phase 2 PMS trials and received FDA SPA agreement for a planned Phase 3b ALS trial.
amyotrophic-lateral-sclerosis-(als)progressive-multiple-sclerosis-(pms)alzheimer's-diseaseneurodegenerative-diseasescurrent-good-manufacturing-practice-(cgmp)fda-fast-track-designationfda-orphan-drug-statusema-orphan-drug-status
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/BCLI
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
NurOwn (MSC-NTF cells)platformAutologous cell therapy platform using bone marrow-derived MSCs induced to secrete neurotrophic factors for treatment of ALS, progressive MS, and Alzheimer's disease.

Partnerships

PartnerTypeDescription
Ramot (Tel Aviv University technology transfer company)licensingIsraeli Subsidiary holds exclusive rights to commercialize NurOwn technology through a licensing agreement with Ramot.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/BCLI/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub